Background & Aims: Direct Antiretroviral Agents (DAAs), sofosbuvir-based therapies,
have opened a new era in the treatment of chronic HCV infection. The aim of the study was to investigate
the potential use of baseline and in serial serum, AFP levels as a predictor for response to DAAs
in patients with Chronic Hepatitis C.
Methods: This multicenter observational study was carried out on 1716 chronic hepatitis C virusinfected
patients who received direct anti-viral drugs for 12 weeks. The primary end point was sustained
virological response at 12 weeks after the end of treatment determined by quantitative PCR for
HCV RNA. Serum AFP was quantitatively assessed at baseline then after 12week after stoppage of
Results: SVR12 rate was 97.8%. Elevated serum AFP was significantly higher in non -SVR group p
value (<0.001). There was a significantly marked decrease in AFP after treatment in comparison to
pretreatment values. The multivariate logistic regression analysis on the resulting significant variable
from the univariate analysis revealed that only AFP was significantly related to the response to direct
antiviral therapy in patients with chronic hepatitis C with p <0.001, OR 1.10 (95% CI 1.07:1.12). Other
sociodemographic (e.g. Age, gender, BMI, ..) or laboratory factors (Hb, ANC, WBCs, …) did not
show any significant association with the patients’ response to treatment.
Conclusions: Serum AFP levels were a predictor for response in patients with chronic HCV with the
administration of direct antiviral drugs.